Ontology highlight
ABSTRACT: Context
In postmenopausal osteoporotic women, denosumab fully inhibits teriparatide-induced bone resorption at approved doses. This property of denosumab is distinct from that of alendronate and likely contributes to the efficacy of combination denosumab and teriparatide therapy. Whether denosumab fully inhibits bone resorption when challenged by a higher dose of teriparatide is unknown.Objective
We aimed to define the comparative ability of denosumab and alendronate to block the acute proresorptive effects of high-dose teriparatide.Design, setting, and participants
In this randomized controlled trial, bone resorption (serum C-telopeptide [CTX]) was measured in 25 postmenopausal women prior to and 4 hours after a single 40-μg sc teriparatide injection. Subjects then
SUBMITTER: Tsai JN
PROVIDER: S-EPMC5393530 | biostudies-literature | 2015 Jul
REPOSITORIES: biostudies-literature